CLINUVEL PHARMACEUTICALS LTD (Seite 2202)
eröffnet am 24.04.07 13:00:35 von
neuester Beitrag 17.05.24 07:54:43 von
neuester Beitrag 17.05.24 07:54:43 von
Beiträge: 22.264
ID: 1.126.403
ID: 1.126.403
Aufrufe heute: 12
Gesamt: 4.027.170
Gesamt: 4.027.170
Aktive User: 0
ISIN: AU000000CUV3 · WKN: A0JEGY
9,1600
EUR
-1,74 %
-0,1625 EUR
Letzter Kurs 22.05.24 Lang & Schwarz
Neuigkeiten
| TitelBeiträge |
|---|
28.03.24 · globenewswire  |
07.03.24 · EQS Group AG |
05.03.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 11,470 | +36,39 | |
| 1,0800 | +28,56 | |
| 2,1800 | +27,49 | |
| 1,9900 | +20,61 | |
| 10.777,50 | +19,75 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,2850 | -13,45 | |
| 10,551 | -13,94 | |
| 0,5701 | -16,77 | |
| 2,5100 | -17,43 | |
| 2,2001 | -20,57 |
Beitrag zu dieser Diskussion schreiben
Feedback
Viel neues steht da ja auch nicht drin 
Antwort auf Beitrag Nr.: 35.928.780 von runningvomper am 12.11.08 19:00:53http://www.asx.com.au/asxpdf/20081113/pdf/31dkrdvjmjlw50.pdf
http://www.asx.com.au/asxpdf/20081113/pdf/31dkqzd16rgmys.pdf
http://www.asx.com.au/asxpdf/20081113/pdf/31dkqxx7kd53s8.pdf
http://www.asx.com.au/asxpdf/20081113/pdf/31dkqzd16rgmys.pdf
http://www.asx.com.au/asxpdf/20081113/pdf/31dkqxx7kd53s8.pdf
Antwort auf Beitrag Nr.: 35.438.464 von runningvomper am 06.10.08 17:02:31guter Umsatz heute für "unsere" Verhältnisse - kommt da was?
In stürmischen Zeiten scheint ja clinuvel wie ein Fels in der Brandung zu stehen. 
Trading Spotlight
Clinuvel commences Phase II trial in Photodynamic Therapy
http://clinuvel.com/resources/pdf/asx_announcements/2008/200…
http://clinuvel.com/resources/pdf/asx_announcements/2008/200…
Habe zu dem letzten "open briefing" vom 01.08.2008 noch eine Frage an cuv gestellt, die ich hier samt Antwort nochmal zum Nachlesen einstelle:
there is something that needs to be explained to me according to your latest open briefing from august 1st.
mr wolgen said that clinuvel does probably not qualify for the
support of a clinical research grant. he referred to a "first analysis".
what does this mean? does this affect the plan to obtain us fda ind status in any way? where can i learn more about the "first analysis" mr wolgen was talking about and why will cuv probably not qualify for this support?
Antwort von Colin Mackie:
Thank you for your interest in Clinuvel and our photoprotective afamelanotide.
In response to your enquiry regarding clinical research grants in the US.
There are a vast number of US research grants available.
They each have their own criteria required to qualify.
Our first review (first analysis) of these criteria has led us to believe that we may not qualify.
Our cash position, at $50m, is a factor here.
We will of course continue to review these criteria and any opportunity to obtain funding.
This does not affect our plans to lodge an IND.
Our current program is fully costed and funded.
May I invite you to visit the next generation www.clinuvel.com for all the latest news and information on Clinuvel and Photoprotection and the progress of afamelanotide to commercialization.
Regards
Colin Mackie
Head of Corporate Development
Level 11 /
330 Collins Street
Melbourne Victoria 3000 Australia
Tel +61 3 9660 4900
Fax +61 3 9660 4999
clinuvel.com
there is something that needs to be explained to me according to your latest open briefing from august 1st.
mr wolgen said that clinuvel does probably not qualify for the
support of a clinical research grant. he referred to a "first analysis".
what does this mean? does this affect the plan to obtain us fda ind status in any way? where can i learn more about the "first analysis" mr wolgen was talking about and why will cuv probably not qualify for this support?
Antwort von Colin Mackie:
Thank you for your interest in Clinuvel and our photoprotective afamelanotide.
In response to your enquiry regarding clinical research grants in the US.
There are a vast number of US research grants available.
They each have their own criteria required to qualify.
Our first review (first analysis) of these criteria has led us to believe that we may not qualify.
Our cash position, at $50m, is a factor here.
We will of course continue to review these criteria and any opportunity to obtain funding.
This does not affect our plans to lodge an IND.
Our current program is fully costed and funded.
May I invite you to visit the next generation www.clinuvel.com for all the latest news and information on Clinuvel and Photoprotection and the progress of afamelanotide to commercialization.
Regards
Colin Mackie
Head of Corporate Development
Level 11 /
330 Collins Street
Melbourne Victoria 3000 Australia
Tel +61 3 9660 4900
Fax +61 3 9660 4999
clinuvel.com
analyse vom 29. August 2008
http://www.clinuvel.com/resources/pdf/analyst_reports/08-08-…
http://www.clinuvel.com/resources/pdf/analyst_reports/08-08-…
Antwort auf Beitrag Nr.: 34.947.980 von runningvomper am 02.09.08 15:48:05Ich glaube, nach dem Ausstieg von ACM haben wir die Tiefststände gesehen. Langsam dürfte es wieder nordwärts gehen. Sollte Clinuvel eine Zulassung bekommen sieht der Kurs ganz anders aus.
Ich kaufe auf jeden Fall noch zu!
Ich kaufe auf jeden Fall noch zu!
Ein Jahrestiefsstand jagd den nächsten - ob man jetzt anfangen sollte nachzukaufen? Was meint ihr?
Durchsuchen
07.03.24 · EQS Group AG · Clinuvel Pharmaceuticals |
06.01.24 · wallstreetONLINE NewsUpdate · Evotec |
06.01.24 · wallstreetONLINE Redaktion · Evotec |
04.10.23 · wO Chartvergleich · Bayer |
20.09.23 · wO Chartvergleich · Borussia Dortmund |